Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1976 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: Metoprolol, Nebivolol; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension (HTN)
Interventions: QCZ484; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 19
States / cities: Garden Grove, California • Los Angeles, California • Brandon, Florida + 16 more

Conditions: Hyperlipidemia, Hypertension
Interventions: HeartBeet Clinic, Self-paced education; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions: AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension, Mineralocorticoid Receptor Antagonist
Interventions: CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Hypertension
Interventions: Nicardipine; Drug
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Supine Applanating Prototype; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Isolated Systolic Hypertension, Endothelial Dysfunction
Interventions: 6R-BH4, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Living Kidney Donation, Hypertension, Nephrectomy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Hyperlipidemia
Interventions: Free Generic Samples (hydrochlorothiazide, simvastatin); Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Pressure, Colorectal Cancer
Interventions: Motivational Interviewing, Patient Navigation; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years and older · Male only
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Diseases, Hypertension, Diabetes, Hyperlipidemia, Kidney Disease, Obesity, Smoking
Interventions: Inspire HER Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 30 Years to 79 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more

Conditions: Hypertension
Interventions: Health coaching, Health coaching plus home titration; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 30 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Hypertension, Stroke, TIA, Vascular Diseases
Interventions: Use of Omron Home Blood Pressure Cuff; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension Stage 1
Interventions: brain natriuretic peptide, no-added salt diet; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: Sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more

Conditions: Hypertension
Interventions: BP Track; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Pigment Dispersion Syndrome With and Without Glaucoma

Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

HeartBeet Clinic Pilot Trial

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

Automated Applanation Tonometry

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Assessment of Risks of Perinephric Fat Thickness to Adverse Renal Outcomes Post Donor Nephrectomy

The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians

Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention

Inspire HER: Inspiring the Heart and Emotions for Radical Health

The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Treating to Target for Patients With Hypertension

Predicitve Use of Spot Urine Protein/Creatinine Ratios in Preeclampsia

Improving Blood Pressure Control in Stroke Patients by Increasing Access to a Home Blood Pressure Monitor

B-type Natriuretic Peptide (BNP) in Human Hypertension

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Utilizing Consumer Health Informatics to Support Management of Hypertension by Clinical Pharmacists in Primary Care